Blackboxstocks (BLBX) Corporate Presentation from NobleCon18Research, News and Market Data on BlackboxstocksNobleCon 18 Complete Rebroadcast
|
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
‌


Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌


6/25/2026
Health
Release – MariMed Submits DEA Registration Applications For State-Licensed Medical Cannabis Businesses
MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator, today announced the Company has submitted applications with the U.S. Drug Enforcement Agency (“DEA”) to...
2 min read
‌


6/25/2026
Uncategorized
Release – Snail Games Unveils Upcoming PixARK: Terracrypt DLC, Highlights 2026 Steam Summer Sale Promotions, and Continued Bellwright Console Port Momentum
Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, provided an update on recent portfolio developments, including the announcement...
5 min read
‌


6/25/2026
Health
Release – NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive biomarker findings from its Phase 2, randomized, double-blind, placebo-controlled proof-of-concept...
7 min read
‌


6/25/2026
Health
Release – MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part...
6 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.